Stocky turns companies like PRISM BIOLAB CO LTD into a fun, safe way to learn investing — a virtual portfolio, live scores & charts, and real analyst data, with no real money.
Try Stocky free →Avoid. 206A.T scores poorly on Value Compounder metrics (10/100), indicating weak earnings quality or unfavorable capital returns relative to valuation. Leadership Alignment is below median (52/100), suggesting misaligned incentives or governance concerns that may not protect shareholder interests. Vulnerability Profile is neutral (50/100), offering no offsetting moat or structural advantage. The combination of weak capital efficiency and middling leadership governance does not justify investmen
Every stock is scored across six proprietary dimensions built for retail investors who want Buffett-quality analysis without a Bloomberg subscription. Here's the actual snapshot for PRISM BIOLAB CO LTD:
Quality + moat + leadership + valuation + sentiment fused into a single 0–100 number. When you see 30/100, you know instantly whether to dig deeper or skip.
Pricing power, switching costs, network effects, and 10-year ROIC data. Same framework Morningstar charges for — free inside Stocky.
Founder tenure, insider ownership, CEO pay reasonableness, long-term value creation. Six factors, one score — turns "trust the CEO" into evidence.
Customer concentration, supply chain, refinancing walls, regulatory exposure. Stocky maps knowable fragilities so you're never blindsided.
Every score backtested against real S&P 500 returns. See how "Elite" (90+ Verdict) picks have performed vs the index — no black boxes.
Analyst target shifts, insider buys, big moves — plus a monthly Portfolio Health Report telling you what's actually driving your returns.
Stocky rates PRISM BIOLAB CO LTD (206A.T) at 30/100 — an Avoid — fundamentals or risks are too weak. The score fuses business quality, moat width, leadership alignment, valuation and analyst signal into a single number. Avoid. 206A.T scores poorly on Value Compounder metrics (10/100), indicating weak earnings quality or unfavorable capital returns relative to valuation. Leadership Alignment is below median (52/100), suggesting misaligned incentives or gove
206A.T's current Stocky Verdict is 30/100, placing it in the "Avoid" band. This composite combines a 10/100 Compounder score, 52/100 Leadership, Moat rating, and analyst signal.
Stocky hasn't finalised a Moat Score for PRISM BIOLAB CO LTD yet — the analysis draws from ROIC trends, pricing power evidence, and competitive-position filings.
PRISM BIOLAB CO LTD scores 52/100 on Leadership Alignment. Higher = more founder involvement, higher insider ownership, sensible pay, and evidence of long-term capital allocation discipline.
PRISM BIOLAB CO LTD's Vulnerability Profile scores 50/100 (higher = more resilient). The profile flags customer concentration, supply chain, refinancing walls and regulatory risks specific to PRISM BIOLAB CO LTD.
Sign up free and unlock the full analysis on 206A.T — the same tools professional analysts use, personalised to your portfolio:
Free forever tier includes 5 Verdict lookups a day. Plus €19/mo unlocks everything above. Cancel any time.
This page is just a preview. Open the live, interactive version for the full picture:
Or jump straight to the interactive dashboard for 206A.T in the app.
